UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies

Warnatz, Klaus; Jolles, Stephen; Agostini, Carlo; Vianello, Fabrizio; Borte, Michael; Bethune, Claire; Grigoriadou, Sofia; ... Cook, Matthew C; + view all (2022) Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies. Clinical Immunology , 236 , Article 108938. 10.1016/j.clim.2022.108938.

[thumbnail of Lowe_final_Lowe_YCLIM-D-21-00800_R1.pdf] Text
Lowe_final_Lowe_YCLIM-D-21-00800_R1.pdf
Access restricted to UCL open access staff until 5 February 2023.

Download (1MB)

Abstract

Many patients with immunodeficiencies require lifelong immunoglobulin replacement therapy (IgRT). In a multicenter, randomized, open-label, crossover, non-inferiority 3-month-trial, we compared the impact of the subcutaneous immunoglobulin Gammanorm® administered via pump or syringe (rapid push). Primary endpoint was the life quality index (LQI), secondary endpoints were QoL (SF36v2), satisfaction (TSQM-11), disease and treatment burden (PRISM), incidence of infections and adverse events (AE), treatment costs, and IgG levels. 28/30 patients completed the study. Most of the endpoints were comparable. Drug administrations with rapid push were more frequent, but reduced total time expenditure and some costs. Of the TSQM-11/LQI/SF36 components only "treatment interference with daily activities" was superior with pump and two QoL domains with rapid push. Both delivery devices showed favorable safety. Rapid push was preferred by 34.5% of patients. It proved to be an efficacious and cost-effective alternative to pumps adding to patient choice and increasing flexibility during long-term IgRT.

Type: Article
Title: Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies
Location: United States
DOI: 10.1016/j.clim.2022.108938
Publisher version: https://doi.org/10.1016/j.clim.2022.108938
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Immunoglobulin replacement therapy, Primary immunodeficiency, Quality of life, Rapid push, Self-treatment
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10143384
Downloads since deposit
1Download
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item